These results are consistent with recent studies in Ewing Sarcoma, a ubiquitously ALT− bone tumor (Table 2), showing sensitivity to ATR inhibition [192] and similar ALT-independent ATR inhibitor sensitivity found in multiple soft tissue sarcomas including leiomyosarcoma, myxofibrosarcoma, and well-differentiated or de-differentiated LPS [183]. The gene discussed is ATR; the disease is bone neoplasm.